5 Best Small Cap Pharma Stocks to Buy Right Now

2. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)

Number of Hedge Fund Holders: 27  

Market Capitalization: $605.78 million 

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is among the best small cap pharma stocks.

TheFly reported on May 7 that IRWD reported its first-quarter 2026 financial performance for the period ended March 31, 2026, showing great year-over-year improvement. Total revenue increased to $106.5 million from $41.1 million, driven primarily by a higher share of U.S. net profits from LINZESS. Total expenses declined significantly to $33.9 million from $70.3 million, reflecting lower R&D, SG&A, and restructuring costs.

The company reported that GAAP net income reached $40.8 million compared with a loss of $37.4 million a year earlier, while non-GAAP net income also turned positive at $40.9 million. Adjusted EBITDA improved sharply to $76.7 million versus a loss of $4.7 million. Cash and cash equivalents rose to $220.5 million, with continued operating cash generation and improved profitability across core segments.

Beyond financials, on May 4, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) also shared new data from a healthcare provider survey presented at Digestive Disease Week 2026 focused on treatment approaches in short bowel syndrome and the use of total parenteral nutrition. Providers highlighted the clinical goal of reducing reliance on TPN to improve patient quality of life and limit complications such as infections, thrombosis, fatigue, and line-related pain.

Most respondents prioritized lowering the number of days patients require TPN each week, while others focused on reducing daily infusion time, with fewer emphasizing volume reduction. The findings underscored the significant long-term burden of TPN dependence, particularly complications linked to central venous access, which were identified as among the most distressing for patients and key limitations in current treatment approaches for short bowel syndrome.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a biopharmaceutical company focused on developing and commercializing transformative therapies for gastrointestinal (GI) and rare diseases.